# Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris

> **NCT02310646** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 219 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 90100 Aerosol Foam
- **DRUG:** Daivobet® gel

## Key facts

- **NCT ID:** NCT02310646
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02310646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02310646, "Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02310646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*